{content}

Study list

MIViral

Switzerland
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

BEACON

United Kingdom
|
2023-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

Gras

Spain
|
2023-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

Mischke

Germany
|
2023
  • Adults (18-64 years)
  • General population
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation
  • Neurostimulation

MULTI-COVID

Italy
|
2023-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

VERDIQual

United Kingdom Thailand Italy Nigeria
|
2023-2025
  • Adults (18-64 years)
  • Monkeypox virus
  • Mpox

Drennan

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • People at high risk of STIs
  • STD/STI clinic
  • Monkeypox virus
  • Mpox
  • Sexually transmitted infection
  • Pharmacological intervention
  • Vaccination

Drysdale 3

United Kingdom
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Primary care
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir

SIREN Winter Pressures sub-study

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Healthcare workers
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

HemCOV

Sweden
|
2022-2037
  • Adults (18-64 years)
  • General population
  • Community
  • SARS-CoV-2
  • Post-COVID-19

Meuris

Belgium
|
2022-2025
  • Adults (18-64 years)
  • People at high risk of STIs
  • Men who have sex with men
  • Hospital
  • Outpatient clinic
  • Monkeypox virus
  • Mpox

PreVitaCOV

Germany
|
2022-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Immunomodulator
  • Prednisolone
  • Vitamin B1
  • Vitamin B12
  • Vitamin B6

DELong#3

Italy
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Probiotic

Aguareles

Spain
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Plitidepsin

Armstrong

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Lifestyle

BUCOSS RSV 60+

Germany
|
2022-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

Costantino

Italy
|
2022-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

RAPID

Netherlands
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

ErgoLoCo

Germany
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

Kuhn

Germany
|
2022
  • General population
  • Adolescents (12-17 years)
  • Non-hospital health centre
  • Telemedicine
  • SARS-CoV-2
  • Post-COVID-19

EuCARE-SCHOOLS

Italy Portugal Mexico
|
2022-2024
  • Adults (18-64 years)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • SARS-CoV-2
  • Acute COVID-19
  • Nasopharyngeal swab
  • Non pharmacological intervention

Chynkiamis

Greece
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Community
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation

Faulkner

United Kingdom
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Post-COVID-19
  • Non pharmacological intervention
  • Rehabilitation
  • Physical activity

Ferrari

Italy
|
2022-2023
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Emergency department
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection